Cell Therapy News Volume 22.10 | Mar 22 2021

    0
    71







    2021-22-03 | CTN 22.10


    Cell Therapy News by STEMCELL Technologies
    Vol. 22.10 – 22 March, 2021
    TOP STORY

    Skeletal Muscle Regeneration via the Chemical Induction and Expansion of Myogenic Stem Cells In Situ or In Vitro

    Scientists showed that myogenic stem cells—which were selectively expanded from readily obtainable dermal fibroblasts or skeletal muscle stem cells using a specific cocktail of small molecules and transplanted into muscle injuries in adult, aged or dystrophic mice—led to functional muscle regeneration in the three animal models.
    [Nature Biomedical Engineering]

    Abstract

    Guide to everything you need to know about cell separation.
    PUBLICATIONSRanked by the impact factor of the journal

    RNA-Seq of Human T Cells after Hematopoietic Stem Cell Transplantation Identifies Linc00402 as a Regulator of T Cell Alloimmunity

    Linc00402 was increased in donor T cells from patients who underwent allogeneic cardiac transplantation and in murine T cells.
    [Science Translational Medicine]

    Abstract

    A Pulsatile Release Platform Based on Photo-Induced Imine-Crosslinking Hydrogel Promotes Scarless Wound Healing

    Scientists developed a wound dressing material based on an integrated photo-crosslinking strategy and a microcapsule platform with pulsatile release of TGF-β inhibitor to achieve spatiotemporal specificity for skin wounds.
    [Nature Communications]

    Full Article

    Gene Therapy for a Murine Model of Eosinophilic Esophagitis

    Researchers hypothesized that a single administration of an adeno‐associated virus coding for an anti‐eosinophil monoclonal antibody that induces eosinophil clearance would treat on a persistent basis a murine model of eosinophilic esophagitis.
    [Allergy]

    Abstract

    In Vivo Survival and Differentiation of Friedreich Ataxia iPSC‐Derived Sensory Neurons Transplanted in the Adult Dorsal Root Ganglia

    To explore cell replacement therapies as a possible approach to treat Friedreich ataxia (FRDA), scientists examined transplantation of sensory neural progenitors derived from human embryonic stem cells and FRDA induced pluripotent stem cells (iPSCs) into adult rodent dorsal root ganglia regions.
    [Stem Cells Translational Medicine]

    Full Article

    Intra-Arterial Transplantation of Stem Cells in Large Animals as a Minimally-Invasive Strategy for the Treatment of Disseminated Neurodegeneration

    Researchers investigated the feasibility and safety of MRI-guided transplantation of glial restricted precursors and mesenchymal stem cells in dogs suffering from ALS-like disease, degenerative myelopathy.
    [Scientific Reports]

    Full Article

    Anti-Mucin 1 Chimeric Antigen Receptor T Cells for Adoptive T Cell Therapy of Cholangiocarcinoma

    Scientists created the fourth-generation CAR construct containing anti-MUC1-single-chain variable fragment and three co-stimulatory domains linked to CD3ζ and evaluated anti-MUC1-CAR4 T cells in cholangiocarcinoma models.
    [Scientific Reports]

    Full Article

    Combined Therapy of Mesenchymal Stem Cells with a GLP-1 Receptor Agonist, Liraglutide, on an Inflammatory-Mediated Diabetic Non-Human Primate Model

    The authors assessed the therapeutic potential of co-administration of human clonal mesenchymal stem cells and liraglutide as a glucagon-like peptide-1 agonist in a non-human primate model with streptozotocin-induced diabetes.
    [Life Sciences]

    Abstract

    Human Periodontal Ligament Stem Cells Transplanted with Nanohydroxyapatite/Chitosan/Gelatin 3D Porous Scaffolds Promote Jaw Bone Regeneration in Swine

    Investigators evaluated the bone regeneration potential of nanohydroxyapatite/chitosan/gelatin three-dimensional porous scaffold with human periodontal ligament stem cells in critical-sized jaw bone defects in minipigs.
    [Stem Cells and Development]

    Abstract


    Dr. Kristina McBurney and Leanna Bedell discuss how you can use social media to advance your scientific career. Watch now.
    REVIEWS

    Retroviral Gene Therapy in Germany with a View on Previous Experience and Future Perspectives

    Investigators provide an overview of contributions to gene therapy made by German clinical and research institutions.
    [Gene Therapy]

    Full Article

    Current Status and Perspective of CAR-T and CAR-NK Cell Therapy Trials in Germany

    The authors take a closer look at the commercial CAR-T cell therapies, as well as on CAR-T and CAR-NK cell products, which are currently under evaluation in clinical trials that are being conducted in Germany.
    [Gene Therapy]

    Full Article

    INDUSTRY AND POLICY NEWS

    Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease

    Sangamo Therapeutics, Inc. announced that the European Medicines Agency’s Committee for Orphan Medicinal Products released details supporting the Orphan Designation of BIVV003, an investigational ex vivo gene-edited cell therapy product candidate currently being evaluated for the treatment of sickle cell disease in the Phase I/II PRECIZN-1 study partnered with Sanofi.
    [Sangamo Therapeutics, Inc.]

    Press Release

    Anixa Biosciences and Moffitt Cancer Center File IND Application for Ovarian Cancer CAR-T Therapy

    Anixa Biosciences, Inc. announced that an IND (Investigational New Drug) application for its ovarian cancer CAR-T therapy has been filed with the FDA.
    [Anixa Biosciences, Inc.]

    Press Release

    Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase I Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency

    Rocket Pharmaceuticals, Inc. announced updated preliminary clinical data from its Phase I trial of RP-L301 for the treatment of Pyruvate Kinase Deficiency, showing durable normalization of hemoglobin levels up to six months following therapy and similar three-month trends in the second patient treated.
    [Rocket Pharmaceuticals, Inc.]

    Press Release

    Celularity Announces Fast Track Designation by the FDA for its Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme

    Celularity, Inc. announced that the company has received Fast Track Designation from the FDA for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, CYNK-001, for the treatment of adults with recurrent glioblastoma multiforme.
    [Celularity, Inc.]

    Press Release

    FEATURED EVENT

    Cell & Gene Meeting on the Mediterranean

    April 6 – 9, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – Gene and Cell Therapy Development for Treatment of Primary Immune Deficiencies

    NIH National Institute of Allergy and Infectious Diseases – Bethesda, Maryland, United States

    Lab Scientist – Tissue and Cellular Therapy

    The University of Iowa – Iowa City, Iowa, United States

    Stem Cell Core Director – Stem Cell Research

    Gladstone Institute – San Francisco, California, United States

    Research Assistant – Cellular Manufacturing

    National University of Ireland Galway – Galway, Ireland

    Research Fellow – RNA Biology

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cell Therapy News Twitter